Results 141 to 150 of about 141,477 (341)

Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients.

European Heart Journal - Cardiovascular Pharmacotherapy, 2019
AIMS Clopidogrel is prescribed for the prevention of atherothrombotic events. While investigations have identified genetic determinants of inter-individual variability in on-treatment platelet inhibition (e.g.
J. Lewis, J. Backman, J. Reny, T. Bergmeijer, B. Mitchell, M. Ritchie, J. Dery, R. Pakyz, L. Gong, K. Ryan, Eun-Young Kim, D. Aradi, I. Férnandez-Cadenas, M. Lee, R. Whaley, J. Montaner, G. Gensini, J. Cleator, Kiyuk Chang, L. Holmvang, W. Hochholzer, D. Roden, S. Winter, R. Altman, D. Alexopoulos, Ho-Sook Kim, M. Gawaz, K. Bliden, M. Valgimigli, R. Marcucci, G. Campo, E. Schaeffeler, N. Dridi, M. Wen, Jae-Gook Shin, P. Fontana, B. Giusti, T. Geisler, M. Kubo, D. Trenk, J. Siller-Matula, J. T. ten Berg, P. Gurbel, M. Schwab, T. Klein, A. Shuldiner   +45 more
semanticscholar   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source

Thromboelastography evaluation of low response to clopidogrel in patients with acute coronary syndrome

International Journal of Gerontology, 2018
Summary: Background: This study aims to measure platelet aggregation with thromboelastography (TEG) and observe low response to clopidogrel in patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy.
Lijia Zhao, Xiaowei Xu, Fenghe Du, Buxing Chen   +3 more
doaj  

Is depression a real risk factor for acute myocardial infarction mortality? A retrospective cohort study [PDF]

, 2019
Background: Depression has been associated with a higher risk of cardiovascular events and a higher mortality in patients with one or more comorbidities.
Baldo, V., Baldovin, T., Bertoncello, C., Buja, A., Casale, P., Cocchio, S., Fonzo, M., Furlan, P.   +7 more
core   +1 more source

Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study

Clinical Pharmacology &Therapeutics, EarlyView.
The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel‐based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical
Henk‐Jan Guchelaar, Cathelijne H. van der Wouden, Lisanne E. N. Manson, Heshu Abdullah‐Koolmees, Kathrin Blagec, Tanja Blagus, Stefan Böhringer, Erika Cecchin, Ka‐Chun Cheung, Vera H. M. Deneer, Siv Jonsson, Candace Joefield‐Roka, Katja S. Just, Mats O. Karlsson, Lidija Konta, Rudolf Koopmann, Marjolein Kriek, Thorsten Lehr, Christina Mitropoulou, Victoria Rollinson, Rossana Roncato, Matthias Samwald, Elke Schaeffeler, Maria Skokou, Matthias Schwab, Daniela Steinberger, Julia C. Stingl, Roman Tremmel, Richard M. Turner, Mandy H. van Rhenen, Cristina L. Dávila‐Fajardo, Vita Dolžan, George P. Patrinos, Munir Pirmohamed, Gere Sunder‐Plassmann, Giuseppe Toffoli, Jesse J. Swen, Ubiquitous Pharmacogenomics Consortium   +37 more
wiley   +1 more source

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Journal of the American Medical Association (JAMA), 2011
CONTEXT High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined.
M. Price, P. Berger, P. Teirstein, J. Tanguay, D. Angiolillo, D. Spriggs, S. Puri, M. Robbins, K. Garratt, O. Bertrand, M. Stillabower, Joseph R. Aragon, D. Kandzari, C. Stinis, Michael S. Lee, S. Manoukian, C. Cannon, N. Schork, E. Topol   +18 more
semanticscholar   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source

THE EFFECTIVENESS OF CLOPIDOGREL AS AN ANTITHROMBOTIC COMPARED TO TICLOPIDINE AND ASPIRIN (META-ANALYSIS)

Jurnal Farmasi Sains dan Komunitas, 2017
Clopidogrel, an antithrombotic drug, has been proven by FDA as Plavix® was initially used for the prevention of vascular occlusive that cause of myocardial infarction, stroke, and vascular death in patients with atherosclerosis and then it is used to ...
Titien Siwi Hartayu, Dewi Setyaningsih
doaj   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients

Neurology International, 2015
The specific action of omega-3 fatty acid ethyl esters (OFA) in preventing cerebrovascular disease remains unknown, but research has demonstrated multiple possible mechanisms.
Ping Li, Haris Kamal, Melissa Baxter, Bijal K. Mehta   +3 more
doaj   +1 more source